Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...
Britain is studying the use of Eli Lilly's weight loss drug, Tirzepatide, to address long-term sickness impacting its economy ...
Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...
In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...